WallStreetZenWallStreetZen

NYSEMKT: LCTX
Lineage Cell Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for LCTX

Based on 4 analysts offering 12 month price targets for Lineage Cell Therapeutics Inc

Min Forecast
$3.00+130.77%
Avg Forecast
$6.25+380.77%
Max Forecast
$9.00+592.31%

Should I buy or sell LCTX stock?

Based on 4 analysts offering ratings for Lineage Cell Therapeutics Inc.

Strong Buy
Strong Buy
3 analysts 75%
Buy
1 analysts 25%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although LCTX's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates LCTX as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their LCTX stock forecasts and price targets.

LCTX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-05-04
lockedlocked$00.00+00.00%2026-04-28
lockedlocked$00.00+00.00%2026-03-25Find Out Why
lockedlocked$00.00+00.00%2026-03-24

1 of 1

Forecast return on equity

Is LCTX forecast to generate an efficient return?

Company
75.52%
Industry
85.8%
Market
169.74%
LCTX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is LCTX forecast to generate an efficient return on assets?

Company
37.14%
Industry
29.42%
LCTX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

LCTX earnings per share forecast

What is LCTX's earnings per share in the next 3 years based on estimates from 10 analysts?

Avg 1 year Forecast
-$0.06
Avg 2 year Forecast
-$0.09
Avg 3 year Forecast
$0.04

LCTX revenue forecast

What is LCTX's revenue in the next 3 years based on estimates from 9 analysts?

Avg 1 year Forecast
$27.9M+88.61%
Avg 2 year Forecast
$15.0M+1.49%
Avg 3 year Forecast
$47.6M+221.75%
LCTX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

LCTX revenue growth forecast

How is LCTX forecast to perform vs Biotechnology companies and vs the US market?

Company
39.34%
Industry
36.05%
Market
13.75%
LCTX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
LCTX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

LCTX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
LCTX$1.32$6.25+373.48%Strong Buy
TENX$12.36$34.50+179.13%Strong Buy
IVVD$1.11$10.00+800.90%Strong Buy
NAUT$2.54$4.00+57.48%Strong Buy
RZLT$3.34$6.20+85.63%Strong Buy
View Top Biotech Stocks

Lineage Cell Therapeutics Stock Forecast FAQ

Is Lineage Cell Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 4 Wall Street analysts covering (NYSEMKT: LCTX) stock is to Strong Buy LCTX stock.

Out of 4 analysts, 3 (75%) are recommending LCTX as a Strong Buy, 1 (25%) are recommending LCTX as a Buy, 0 (0%) are recommending LCTX as a Hold, 0 (0%) are recommending LCTX as a Sell, and 0 (0%) are recommending LCTX as a Strong Sell.

If you're new to stock investing, here's how to buy Lineage Cell Therapeutics stock.

What is LCTX's earnings growth forecast for 2026-2028?

(NYSEMKT: LCTX) Lineage Cell Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.87%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.38%.

Lineage Cell Therapeutics's earnings in 2026 is -$64,206,000.On average, 10 Wall Street analysts forecast LCTX's earnings for 2026 to be -$15,631,003, with the lowest LCTX earnings forecast at -$34,203,726, and the highest LCTX earnings forecast at $28,793,953. On average, 10 Wall Street analysts forecast LCTX's earnings for 2027 to be -$21,290,074, with the lowest LCTX earnings forecast at -$34,203,726, and the highest LCTX earnings forecast at $5,235,264.

In 2028, LCTX is forecast to generate $9,099,388 in earnings, with the lowest earnings forecast at -$26,874,356 and the highest earnings forecast at $125,646,341.

What is LCTX's revenue growth forecast for 2026-2028?

(NYSEMKT: LCTX) Lineage Cell Therapeutics's forecast annual revenue growth rate of 39.34% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 36.05%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.75%.

Lineage Cell Therapeutics's revenue in 2026 is $14,779,000.On average, 9 Wall Street analysts forecast LCTX's revenue for 2026 to be $6,948,940,675, with the lowest LCTX revenue forecast at $2,059,453,215, and the highest LCTX revenue forecast at $15,156,089,845. On average, 9 Wall Street analysts forecast LCTX's revenue for 2027 to be $3,739,225,127, with the lowest LCTX revenue forecast at $1,319,286,577, and the highest LCTX revenue forecast at $6,918,526,283.

In 2028, LCTX is forecast to generate $11,854,383,226 in revenue, with the lowest revenue forecast at $1,319,286,577 and the highest revenue forecast at $48,044,767,412.

What is LCTX's forecast return on assets (ROA) for 2026-2029?

(NYSEMKT: LCTX) forecast ROA is 37.14%, which is higher than the forecast US Biotechnology industry average of 29.42%.

What is LCTX's Price Target?

According to 4 Wall Street analysts that have issued a 1 year LCTX price target, the average LCTX price target is $6.25, with the highest LCTX stock price forecast at $9.00 and the lowest LCTX stock price forecast at $3.00.

On average, Wall Street analysts predict that Lineage Cell Therapeutics's share price could reach $6.25 by May 4, 2027. The average Lineage Cell Therapeutics stock price prediction forecasts a potential upside of 373.48% from the current LCTX share price of $1.32.

What is LCTX's Earnings Per Share (EPS) forecast for 2026-2028?

(NYSEMKT: LCTX) Lineage Cell Therapeutics's current Earnings Per Share (EPS) is -$0.28. On average, analysts forecast that LCTX's EPS will be -$0.06 for 2026, with the lowest EPS forecast at -$0.14, and the highest EPS forecast at $0.12. On average, analysts forecast that LCTX's EPS will be -$0.09 for 2027, with the lowest EPS forecast at -$0.14, and the highest EPS forecast at $0.02. In 2028, LCTX's EPS is forecast to hit $0.04 (min: -$0.11, max: $0.50).

What is LCTX's forecast return on equity (ROE) for 2026-2029?

(NYSEMKT: LCTX) forecast ROE is 75.52%, which is considered strong.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.